Explore
Validate
Learn
ImmunohistochemistryAntibody data
- Antibody Data
- Antigen structure
- References [5]
- Comments [0]
- Validations
- Immunohistochemistry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- MA1-90059 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- Anti-ALK Monoclonal Antibody (SP8)
- Antibody type
- Monoclonal
- Antigen
- Recombinant full-length protein
- Description
- MA1-90059 detects ALK-80 from human samples. MA1-90059 has been successfully used in immunohistochemistry (paraffin tissue) applications. Formalin fixed paraffin embedded tissue sections require high temperature antigen unmasking with 10mM citrate buffer, p.H. 6.0 prior to immunostaining. The MA1-90059 immunogen is: Recombinant protein corresponding to a region, which spans the tyrosine kinase catalytic domain and part of the C-terminus of the NPM-ALK transcript
- Reactivity
- Human
- Host
- Rabbit
- Isotype
- IgG
- Antibody clone number
- SP8
- Vial size
- 6 mL
- Concentration
- Lot Dependent
- Storage
- 4° C, do not freeze
Submitted references High anaplastic lymphoma kinase immunohistochemical staining in neuroblastoma and ganglioneuroblastoma is an independent predictor of poor outcome.
Conditional TPM3-ALK and NPM-ALK transgenic mice develop reversible ALK-positive early B-cell lymphoma/leukemia.
Diagnostic and differential diagnostic criteria of lymphoid neoplasms in bone marrow trephine biopsies: a study of 87 cases.
Development of a conditional bioluminescent transplant model for TPM3-ALK-induced tumorigenesis as a tool to validate ALK-dependent cancer targeted therapy.
Development of a conditional bioluminescent transplant model for TPM3-ALK-induced tumorigenesis as a tool to validate ALK-dependent cancer targeted therapy.
Duijkers FA, Gaal J, Meijerink JP, Admiraal P, Pieters R, de Krijger RR, van Noesel MM
The American journal of pathology 2012 Mar;180(3):1223-31
The American journal of pathology 2012 Mar;180(3):1223-31
Conditional TPM3-ALK and NPM-ALK transgenic mice develop reversible ALK-positive early B-cell lymphoma/leukemia.
Giuriato S, Foisseau M, Dejean E, Felsher DW, Al Saati T, Demur C, Ragab A, Kruczynski A, Schiff C, Delsol G, Meggetto F
Blood 2010 May 20;115(20):4061-70
Blood 2010 May 20;115(20):4061-70
Diagnostic and differential diagnostic criteria of lymphoid neoplasms in bone marrow trephine biopsies: a study of 87 cases.
Horváth E, Mezei T, Pávai Z, Turcu M, Demian S, Tóth E, Chira L, Jung I
Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie 2009;50(3):399-406
Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie 2009;50(3):399-406
Development of a conditional bioluminescent transplant model for TPM3-ALK-induced tumorigenesis as a tool to validate ALK-dependent cancer targeted therapy.
Giuriato S, Faumont N, Bousquet E, Foisseau M, Bibonne A, Moreau M, Al Saati T, Felsher DW, Delsol G, Meggetto F
Cancer biology & therapy 2007 Aug;6(8):1318-23
Cancer biology & therapy 2007 Aug;6(8):1318-23
Development of a conditional bioluminescent transplant model for TPM3-ALK-induced tumorigenesis as a tool to validate ALK-dependent cancer targeted therapy.
Giuriato S, Faumont N, Bousquet E, Foisseau M, Bibonne A, Moreau M, Al Saati T, Felsher DW, Delsol G, Meggetto F
Cancer biology & therapy 2007 Aug;6(8):1318-23
Cancer biology & therapy 2007 Aug;6(8):1318-23
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemical analysis of ALK/CD246 in human Anaplastic lymphoma using an ALK/CD246 monoclonal antibody (Product # MA1-90059).
